Cite
HARVARD Citation
Opdam, F. et al. (n.d.). A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations. European journal of cancer. pp. S1-. [Online].